Statin wars: The heavyweight match- atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease

James J. Dinicolantonio, Carl J. Lavie, Victor L. Serebruany, James H. O'Keefe

Research output: Contribution to journalArticle

Abstract

Statins are a standard of care in many clinical settings, especially for dyslipidemia management, and are used for the primary and secondary prevention of cardiovascular disease. Importantly, not all statins are born equal. The statin class consists of a number of heterogenous drugs, which vary in properties such as potency in lowering low-density lipoprotein cholesterol levels, lipophilicity, renoprotection, increasing high-density lipoprotein cholesterol levels, lowering triglyceride levels, and effects on glucose metabolism and myocardial function. It remains unclear whether these differences significantly impact clinical outcomes or if 1 statin should be preferred over another. This review summarizes the properties of the 2 most potent statins available (atorvastatin and rosuvastatin), as well as assesses the comparative experimental and clinical trials that have been conducted on these 2 agents. We believe that the available body of evidence indicates that atorvastatin may have several advantages over rosuvastatin, despite the latter's greater potency, suggesting that atorvastatin should be the potent statin of choice, especially in treating patients with renal impairment or heart failure with concomitant coronary artery disease. The recent availability of atorvastatin as a generic option gives this drug another practical and compelling advantage over rosuvastatin.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalPostgraduate Medicine
Volume125
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chronic Renal Insufficiency
Atherosclerosis
Heart Failure
Therapeutics
Primary Prevention
Standard of Care
Dyslipidemias
Secondary Prevention
Pharmaceutical Preparations
LDL Cholesterol
HDL Cholesterol
Renal Insufficiency
Rosuvastatin Calcium
Atorvastatin Calcium
Warfare
Coronary Artery Disease
Triglycerides
Cardiovascular Diseases
Clinical Trials

Keywords

  • Atorvastatin
  • Cholesterol
  • Chronic kidney disease
  • Heart failure
  • Rosuvastatin
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statin wars : The heavyweight match- atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. / Dinicolantonio, James J.; Lavie, Carl J.; Serebruany, Victor L.; O'Keefe, James H.

In: Postgraduate Medicine, Vol. 125, No. 1, 01.2013, p. 7-16.

Research output: Contribution to journalArticle

Dinicolantonio, James J. ; Lavie, Carl J. ; Serebruany, Victor L. ; O'Keefe, James H. / Statin wars : The heavyweight match- atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. In: Postgraduate Medicine. 2013 ; Vol. 125, No. 1. pp. 7-16.
@article{1df2d45fe6444e25a7149830de9225e6,
title = "Statin wars: The heavyweight match- atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease",
abstract = "Statins are a standard of care in many clinical settings, especially for dyslipidemia management, and are used for the primary and secondary prevention of cardiovascular disease. Importantly, not all statins are born equal. The statin class consists of a number of heterogenous drugs, which vary in properties such as potency in lowering low-density lipoprotein cholesterol levels, lipophilicity, renoprotection, increasing high-density lipoprotein cholesterol levels, lowering triglyceride levels, and effects on glucose metabolism and myocardial function. It remains unclear whether these differences significantly impact clinical outcomes or if 1 statin should be preferred over another. This review summarizes the properties of the 2 most potent statins available (atorvastatin and rosuvastatin), as well as assesses the comparative experimental and clinical trials that have been conducted on these 2 agents. We believe that the available body of evidence indicates that atorvastatin may have several advantages over rosuvastatin, despite the latter's greater potency, suggesting that atorvastatin should be the potent statin of choice, especially in treating patients with renal impairment or heart failure with concomitant coronary artery disease. The recent availability of atorvastatin as a generic option gives this drug another practical and compelling advantage over rosuvastatin.",
keywords = "Atorvastatin, Cholesterol, Chronic kidney disease, Heart failure, Rosuvastatin, Statins",
author = "Dinicolantonio, {James J.} and Lavie, {Carl J.} and Serebruany, {Victor L.} and O'Keefe, {James H.}",
year = "2013",
month = "1",
doi = "10.3810/pgm.2013.01.2620",
language = "English (US)",
volume = "125",
pages = "7--16",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - Statin wars

T2 - The heavyweight match- atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease

AU - Dinicolantonio, James J.

AU - Lavie, Carl J.

AU - Serebruany, Victor L.

AU - O'Keefe, James H.

PY - 2013/1

Y1 - 2013/1

N2 - Statins are a standard of care in many clinical settings, especially for dyslipidemia management, and are used for the primary and secondary prevention of cardiovascular disease. Importantly, not all statins are born equal. The statin class consists of a number of heterogenous drugs, which vary in properties such as potency in lowering low-density lipoprotein cholesterol levels, lipophilicity, renoprotection, increasing high-density lipoprotein cholesterol levels, lowering triglyceride levels, and effects on glucose metabolism and myocardial function. It remains unclear whether these differences significantly impact clinical outcomes or if 1 statin should be preferred over another. This review summarizes the properties of the 2 most potent statins available (atorvastatin and rosuvastatin), as well as assesses the comparative experimental and clinical trials that have been conducted on these 2 agents. We believe that the available body of evidence indicates that atorvastatin may have several advantages over rosuvastatin, despite the latter's greater potency, suggesting that atorvastatin should be the potent statin of choice, especially in treating patients with renal impairment or heart failure with concomitant coronary artery disease. The recent availability of atorvastatin as a generic option gives this drug another practical and compelling advantage over rosuvastatin.

AB - Statins are a standard of care in many clinical settings, especially for dyslipidemia management, and are used for the primary and secondary prevention of cardiovascular disease. Importantly, not all statins are born equal. The statin class consists of a number of heterogenous drugs, which vary in properties such as potency in lowering low-density lipoprotein cholesterol levels, lipophilicity, renoprotection, increasing high-density lipoprotein cholesterol levels, lowering triglyceride levels, and effects on glucose metabolism and myocardial function. It remains unclear whether these differences significantly impact clinical outcomes or if 1 statin should be preferred over another. This review summarizes the properties of the 2 most potent statins available (atorvastatin and rosuvastatin), as well as assesses the comparative experimental and clinical trials that have been conducted on these 2 agents. We believe that the available body of evidence indicates that atorvastatin may have several advantages over rosuvastatin, despite the latter's greater potency, suggesting that atorvastatin should be the potent statin of choice, especially in treating patients with renal impairment or heart failure with concomitant coronary artery disease. The recent availability of atorvastatin as a generic option gives this drug another practical and compelling advantage over rosuvastatin.

KW - Atorvastatin

KW - Cholesterol

KW - Chronic kidney disease

KW - Heart failure

KW - Rosuvastatin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84875884380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875884380&partnerID=8YFLogxK

U2 - 10.3810/pgm.2013.01.2620

DO - 10.3810/pgm.2013.01.2620

M3 - Article

C2 - 23391667

AN - SCOPUS:84875884380

VL - 125

SP - 7

EP - 16

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -